Workshop report: Schistosomiasis vaccine clinical development and product characteristics.

Mo, Annie X; Colley, Daniel G

Mo, Annie X; Colley, Daniel G.

Afiliación

Mo AX; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA. Electronic address: annie.mo@nih.gov.
Colley DG; Center for Tropical and Emerging Global Diseases and the Department of Microbiology, University of Georgia, Athens, GA, USA.

Vaccine ; 34(8): 995-1001, 2016 Feb 17.

Article en En | MEDLINE | ID: mdl-26721329

RESUMEN

A schistosomiasis vaccine meeting was organized to evaluate the utility of a vaccine in public health programs, to discuss clinical development paths, and to define basic product characteristics for desirable vaccines to be used in the context of schistosomiasis control and elimination programs. It was concluded that clinical evaluation of a schistosomiasis vaccine is feasible with appropriate trial design and tools. Some basic Preferred Product Characteristics (PPC) for a human schistosomiasis vaccine and for a veterinary vaccine for bovine use were also proposed.

Asunto(s)

Esquistosomiasis/prevención & control; Vacunas/uso terapéutico; Animales; Bovinos; Ensayos Clínicos como Asunto; Congresos como Asunto; Salud Global; Humanos; Proyectos de Investigación; Schistosoma

Palabras clave

Clinical development plan (CDP); Preferred product characteristics (PPC); Schistosomiasis; Target product profile (TPP); Vaccine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquistosomiasis / Vacunas Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google